← All articles A small tube of prescription cream on a clean countertop, representing low-dose vaginal estrogen and the barriers to prescribing it.
Estrogen

"What Rachel Rubin told the FDA: what your gynecologist still hasn't heard."

Vaginal estrogen is cheap, barely enters the bloodstream, and cuts UTIs and related mortality. Yet a misplaced black box warning still keeps doctors from prescribing it. Here is the data.

By Annette Thompson · May 12, 2026 · 12 min read

Okay so, imagine this.

Your mother is in the ICU. She has a catheter. She’s postmenopausal, her vaginal and urethral tissue are atrophied — which means the protective epithelial barrier that keeps bacteria from ascending into her bladder is essentially gone. You know exactly what happens next: UTI → bladder → kidneys → bloodstream → sepsis → death. You’ve seen it in patients.

You are a urologist. You know the fix. Your mother has been using it for years. It’s a cream. It costs eleven dollars a month.

You ask the ICU nurses to restart your mother’s prescription for vaginal estrogen.

They refuse.

You ask the pharmacist.

Refused.

You ask the doctor.

Refused.

Not because the cream is dangerous. Because it has a black box warning on the label — the FDA’s most serious caution category — listing risks including breast cancer, stroke, dementia, and blood clots. Every person in that chain saw the box and flinched.

The problem? That warning was written in 2003 based on systemic hormone replacement therapy — estrogen taken orally, swallowed into the bloodstream, circulating everywhere. Not a topical cream applied inside the vagina, where estrogen levels in the blood afterward are, as one researcher testified to the FDA, literally undetectable.

The black box warning was factually wrong for vaginal estrogen products. It was wrong for 22 years.

In July 2025, Dr. Rachel Rubin — urologist, sexual medicine specialist, and the doctor whose mother nearly died in that ICU — stood before an FDA advisory panel and said five words:

“Your label tried to kill my mother.”

Four months later, the FDA removed the black box warning from low-dose vaginal estrogen. 🎉

But here’s the thing. The label changed in November 2025. Your oncologist hasn’t gotten the memo. Your gynecologist is still hedging. And millions of women are still being told to “just use a lubricant.”

Let’s talk about what the science actually says.

What’s Actually Happening to Your Body

Before we get to the data, let me describe something most women experience but few name.

You’re postmenopausal. Or maybe you’re in perimenopause. And things have gotten… dry. Not just uncomfortable — sharp. Burning. Sometimes bleeding after sex. Getting up three times a night to pee. Another UTI, the third one this year. Your doctor keeps prescribing antibiotics. The antibiotics keep working, and then two months later you’re back in the office.

Sound familiar? You’re not describing normal aging. You’re describing Genitourinary Syndrome of Menopause (GSM) — the umbrella term for everything that happens when the estrogen receptors in your vaginal, vulvar, urethral, and bladder tissues go dark.

Here’s the mechanism, because understanding it matters: estrogen maintains the epithelial lining of the vagina and urethra. It keeps the vaginal pH acidic (which means lactobacillus bacteria thrive, and the bad stuff — E. coli, Klebsiella — can’t get a foothold). Without estrogen, the epithelium thins, the pH rises, the lactobacilli disappear, and the uropathogens move in. The pathway from “dry vagina” to “UTI” to “ICU” is a straight biological line.

Unlike hot flashes, which tend to fade over time, GSM doesn’t get better on its own. It progresses. Every year without treatment, the tissue gets a little thinner, the pH a little higher, the infections a little more frequent.

GSM affects somewhere between 50% and 84% of postmenopausal women. Most of them are not being treated. Most of them think dryness is just what happens.

It’s not. And there’s a fix.

The Fix — And Why It’s Safe

Vaginal estrogen is a low-dose, topical preparation — cream, tablet, suppository, or ring — applied directly inside the vagina. The estrogen acts locally on the vaginal and urethral tissue, restoring epithelial thickness, lowering pH, bringing back the lactobacilli, rebuilding the mucosal barrier.

The key word is locally.

The doses involved are microscopic compared to systemic HRT. A Vagifem tablet (estradiol) delivers 10 micrograms — that’s micrograms, not milligrams. A standard HRT patch delivers 50–200 micrograms per day transdermally into the bloodstream. We’re talking a 5–20x difference in dose, applied directly to tissue, not crossing the skin.

And the blood levels confirm it. Dr. James Simon, clinical professor at George Washington University, testified at the same July 2025 FDA hearing:

“You cannot measure [systemic estradiol levels] in the blood.”

Post-menopausal women using low-dose vaginal estrogen show serum estradiol levels at or below the postmenopausal baseline — often literally undetectable on standard assays. And here’s the elegant biology: as the vaginal epithelium restores under estrogen treatment, it becomes a better barrier, so systemic absorption actually decreases over time. The longer you use it, the less gets in.

This is not systemic hormone therapy. The risks don’t transfer.

The UTI and Death Data

Okay, here’s where the research gets striking.

UTI reduction: A meta-analysis of five randomized controlled trials covering 1,936 patients found that vaginal estrogen reduced recurrent UTI risk with a relative risk of 0.42 (95% CI 0.30–0.59). Real-world retrospective data showed that UTI frequency dropped from 3.9 to 1.8 episodes per year — a 51.9% reduction — in women who started vaginal estrogen.

Half. The UTI rate dropped by half.

But the more jaw-dropping numbers come from the urosepsis data, published in the AUA Journals (2024): in postmenopausal women with recurrent UTI, vaginal estrogen users had:

  • Sepsis rate: 10.6% vs. 19.4% in non-users
  • Death rate: 0.42% vs. 1.54% in non-users

That’s nearly a fourfold reduction in death rate from urosepsis — an infection that often starts as a UTI, enters the bloodstream, and triggers the systemic inflammatory cascade that kills roughly 270,000 Americans every year.

Read that again. Women not using vaginal estrogen died of urosepsis at a rate of 1.54%. Women using vaginal estrogen died at 0.42%. For something that starts as a UTI. For something preventable with an eleven-dollar cream.

The American Urological Association 2025 guideline is now explicit: “In patients with GSM and recurrent urinary tract infections, clinicians should recommend local low-dose vaginal estrogen to reduce the risk for future urinary tract infections.” This is a guideline, not a suggestion.

The Breast Cancer Bombshell

Here’s the part that should make every oncologist sit down.

The conventional wisdom — still believed by many oncologists — is that estrogen in any form is dangerous for breast cancer survivors. It’s the reason Dr. Rubin’s mother’s ICU team wouldn’t restart her vaginal estrogen. It’s the reason most gynecologists won’t prescribe vaginal estrogen to any woman who’s had breast cancer, even ER-negative cancers. Even women not on hormone-sensitive treatments.

In 2024, JAMA Oncology published data on 49,237 breast cancer survivors — 84% of whom had ER-positive cancer, 55% were on tamoxifen, 48% were on aromatase inhibitors. These are the patients oncologists are most worried about. And the result?

Hazard ratio: 0.77 (95% CI 0.63–0.94, p=0.01) for breast cancer–specific mortality in vaginal estrogen users vs. non-users.

Let me translate that. An HR of 0.77 means vaginal estrogen users had a 23% lower hazard of dying from breast cancer compared to women who didn’t use it. Statistically significant. p=0.01. In the group of patients everyone was most afraid to treat.

The women most feared to be harmed by any estrogen had better survival when they used vaginal estrogen.

Now — HR 0.77 in an observational study doesn’t prove that vaginal estrogen causes better survival. There’s almost certainly some healthy-user bias (women who are prescribed vaginal estrogen probably have better healthcare access and engagement). This data should be interpreted carefully, not as a headline saying “vaginal estrogen cures cancer.” But here’s the point: in the best evidence we have, from the largest cohort ever studied, in the highest-risk patients, the direction of the signal is the opposite of harm. The systematic review published in AJOG 2024 reached the same conclusion: no significant increase in recurrence or mortality.

The AUA’s 2025 guideline language: “Clinicians should inform patients of the absence of evidence linking local low-dose vaginal estrogen to the development of breast cancer.”

Absence of evidence of harm. In 49,000 breast cancer survivors. And we’re still withholding the cream.

Why Doctors Still Say No

Let’s be honest about the system failure here.

It was the label. For 22 years, vaginal estrogen sat under the same black box warning as oral conjugated equine estrogen plus medroxyprogesterone acetate — the specific formulation used in the 2003 Women’s Health Initiative, in women who were on average 63 years old and already significantly past the initiation window. The black box listed breast cancer, stroke, dementia, blood clots. Every nurse, pharmacist, and physician in every hospital and pharmacy saw that box and acted on it.

The label was never accurate for vaginal estrogen. It was a regulatory copy-paste applied to an entire class of products without distinguishing between drugs that produce systemic blood levels and drugs that don’t.

The oncologist reflex. Even now that the label has changed, oncologists are the last to update. Their training conditioned them to treat any estrogen as contraindicated in cancer patients. Many have not read the JAMA Oncology 2024 data. The conversation in your oncologist’s office is still being driven by 2003 WHI anxiety.

The “just use a lubricant” dodge. Let’s be clear about what lubricants and vaginal moisturizers actually do: they reduce friction and provide temporary comfort. They do nothing for the underlying tissue atrophy. They don’t lower pH. They don’t restore the epithelial barrier. They don’t prevent UTIs. They’re palliative, not therapeutic. Telling a postmenopausal woman with recurrent UTIs to “just use a lubricant” is like telling someone with pneumonia to use cough drops.

Lubricant = symptom comfort. Vaginal estrogen = tissue restoration + infection prevention.

What to Ask For

If you’re postmenopausal and experiencing any of the GSM symptoms — dryness, burning, painful sex, recurrent UTIs, urinary urgency, incontinence — here are your options to discuss with your provider:

  • Vagifem / Yuvafem (estradiol vaginal tablet, 10mcg): insert with a small applicator; nightly for 2 weeks, then twice weekly for maintenance. Generic versions available.
  • Imvexxy (estradiol vaginal insert): similar dosing, slightly different form factor.
  • Estrace cream (estradiol cream): applied with an applicator; flexible dosing.
  • Estring (estradiol vaginal ring): placed in the upper vagina by your provider, lasts 90 days. Good option if you don’t want to remember twice-weekly dosing.
  • Intrarosa / Prasterone (DHEA vaginal suppository): converts locally to estrogen and androgens without introducing estrogen directly — preferred by some oncologists and by women who want to avoid estrogen entirely.

If your oncologist says no to everything: ask specifically about Intrarosa (DHEA), which avoids estrogen itself; and ask for the data supporting their concern. The AUA 2025 guideline explicitly supports prescribing in breast cancer survivors “in the context of multidisciplinary shared decision-making.” That means your voice is part of the decision.

If your GP or gynecologist hasn’t heard about the November 2025 FDA label change removing the black box warning from vaginal estrogen — now you can tell them.

What Other Countries Figured Out First

Here’s the part that makes me genuinely angry.

In September 2023, the United Kingdom made Gina — estradiol 10 mcg vaginal tablet — available over the counter. No prescription. No doctor. No explaining yourself to a pharmacist who read the black box and got nervous. Women 50 and older walk into a Boots or a Superdrug and buy it. Ovesse, an estriol vaginal cream, also went OTC around the same time. Full stop. (I was living in London when Gina launched and used it myself — picking it up at Boots without a prescription felt almost transgressive after years of navigating the US system.)

Meanwhile, the US — as of November 2025 — still requires a prescription for every vaginal estrogen product on the market. This is a product with essentially zero systemic absorption. A product whose estradiol blood levels are, as we’ve now established, literally undetectable. A product that just had its misleading black box warning removed after 22 years of doing damage. The UK made it OTC. We still make you convince a doctor.

Australia is doing something else interesting. In June 2023, Australia’s TGA approved Intrarosa (prasterone/DHEA, 6.5 mg vaginal insert) — still prescription-only there, but notable for what it does. Prasterone converts locally inside vaginal tissue into both estrogen and androgen metabolites. That means it addresses not just dryness and pain (the estrogen pathway) but also sensation and arousal — the androgen pathway that often goes completely untreated. It’s a more comprehensive approach to GSM than estradiol-only products. It’s available in the US under the same Intrarosa brand, also prescription-only, and you’ve probably never heard of it.

The pattern is consistent: other countries are moving faster on vaginal estrogen access. The UK made a product with undetectable blood levels available without a prescription. The US spent those same years maintaining a black box warning your oncologist cannot scientifically defend — and just got around to removing it in late 2025.

We were 22 years late on the label. At least we got there.

Rachel Rubin’s Mother, and the Women Who Didn’t Have a Doctor in the Family

Dr. Rachel Rubin’s mother made it out of the ICU.

She had an advantage: a daughter who was a urologist, who knew what was happening, who kept fighting through the institutional refusal until someone finally listened.

The FDA removed the black box warning in November 2025, partly because of the testimony given that July. The label that drove those refusals is gone.

But labels change faster than habits. The nurse who refused in 2022 is still nursing. The oncologist trained in 2003 still has 2003 instincts. The pharmacist still flinches at anything that once wore a black box.

The women who didn’t have a urologist in the family — the ones who got the UTI, and then the sepsis, and then the ICU stay, and then the ventilator — didn’t get to stand before the FDA and say what almost happened to them.

Vaginal estrogen is not a controversial drug. It’s an eleven-dollar local cream with 50 years of safety data, undetectable blood levels, and a 51% reduction in the thing that kills older women in hospitals.

Ask for it. Share this article with a friend who keeps getting UTIs. Tell your mother. Tell her doctor.

The label changed. The science has been there all along. Now we make sure the people prescribing — and the people asking — know it too. 💪

Annette Thompson is 57, the founder of adoption.com, and a menopause advocate writing about evidence-based women’s health.

Sources

Keep reading

An empty memorial-like row of chairs, evoking the uncounted women lost after the 2002 hormone therapy scare.
Estrogen "18,000 to 91,000 women. Who died because of a bad study."
Free newsletter

Get the research, not the reassurance.

Every issue is free and every claim is sourced. Join women 40+ who are reading the science, asking better questions, and refusing to accept "it's just aging" as an answer.

Subscribe free on Substack